Bridge Pathology Ltd in Bristol is part of the Veterinary Pathology Group. We are a highly dynamic veterinary histopathology and immunohistochemistry laboratory, dedicated to the provision of the highest quality diagnostic pathology services to the veterinary community. At Bridge Pathology, we provide a top quality service and are always keen to answer any queries, offer advice on cases and ultimately help you to provide the best quality care for your patients. If you have any questions about tissues that you are going to be submitting to us or about a report that you have received from us, then please do not hesitate to contact us. We will help wherever we can.
We aim to achieve 24 hour turnaround times, with a full, ECVP/ACVP-style pathological description and clinically-targeted comment provided for every single case. We provide full light microscopic characterisation of tissues, with meticulous attention to those factors that may have the most diagnostic and prognostic value. Using this approach, we can derive the greatest amount of clinically-important information from the biopsy samples that are submitted to us. For all tumour submissions, we provide full evaluation of surgical margins. This is performed in a more rigorous manner than in any other commercial laboratory in the UK and we were involved in developing the ACVP recommendations for biopsy evaluation that are considered ‘gold standard’ pathology practice. All tumours are graded where appropriate. We routinely grade soft tissue sarcomas, mast cell tumours, pulmonary tumours, urinary bladder tumours, mammary carcinomas, intestinal adenomas, endoscopic biopsies, osteosarcomas and lymphomas using recently published data for these tissues.
We offer state-of-the-art diagnostic immunohistochemistry with the widest range of validated and optimised antibodies of any of the UK diagnostic laboratories. This enables us to subclassify tumours further than is possible using H&E- stained tissues alone, enabling optimal treatment of veterinary cancer patients. We also offer quantification of proliferation markers where these have been shown to provide useful prognostic information, for instance for measurement of the Ki67 index in canine mast cell tumours and melanomas.